US Stock Market News | Novavax Pharmaceuticals plunges over 19% as FDA halts its flu vaccine clinical trial

智通财经
2024.10.16 15:50

周三，诺瓦瓦克斯医药股价大幅下跌，截至发稿，该股跌超 19%，报 10.16 美元。消息面上，美国食品药品监督管理局 (FDA) 暂停了该公司计划进行的流感疫苗临床试验，临床暂停是因为单个 CIC 2 期试验参与者发生了严重的运动神经病变事件的自发报告。

智通财经 APP 获悉，周三，诺瓦瓦克斯医药 (NVAX.US) 股价大幅下跌，截至发稿，该股跌超 19%，报 10.16 美元。消息面上，美国食品药品监督管理局 (FDA) 暂停了该公司计划进行的流感疫苗临床试验，临床暂停是因为单个 CIC 2 期试验参与者发生了严重的运动神经病变事件的自发报告。

Source: 智通财经 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.